Why Is Alumis (ALMS) Stock Down -6.16% Today?
Key Takeaways
- Alumis shares fell 6.16% to $9.29, down $0.61 from the prior session's close of $9.90.
- The decline extends a multi-session selloff triggered by the failure of its lead lupus drug candidate, envudeucitinib, in a Phase 2b trial.
- A wave of analyst downgrades and price-target cuts has kept sustained selling pressure on the clinical-stage biotech.
- Notable insider buying by a company director provided only temporary support before shares resumed their slide.
- Traders are now focused on the company's planned pivot toward a biomarker-driven Phase 3 strategy and upcoming regulatory meetings.
Opening Summary
Alumis, Inc. (ALMS) is a San Francisco-based clinical-stage biopharmaceutical company focused on developing oral therapies for autoimmune disorders such as systemic lupus erythematosus (SLE) and Sjögren's syndrome. On Thursday, shares of the company fell 6.16% to $9.29, declining $0.61 from a prior-session close of $9.90. The move downward extended a bruising stretch for the stock, which has been under heavy pressure since the company disclosed that its lead TYK2 inhibitor failed to meet its primary and secondary endpoints in a pivotal mid-stage lupus study. Markets continue to reprice the shares as investors reassess the company's clinical pipeline and path forward.
Failed Lupus Trial Continues to Weigh on Sentiment
The dominant catalyst behind the recent weakness in ALMS is the disappointing readout from the Phase 2b LUMUS trial of envudeucitinib, an investigational oral TYK2 inhibitor being developed for moderate-to-severe systemic lupus erythematosus. The 408-patient study did not meet its primary endpoint, the BICLA response at week 48, nor its secondary endpoints in the overall study population. The three tested dose regimens produced response rates that were numerically higher than placebo but did not reach statistical significance, with the overall result held back by a higher-than-expected placebo response.
The market reaction was swift and severe: the stock, which had been trading above $21 in the sessions before the announcement, collapsed to single digits in a single day. While the company highlighted encouraging results in a pre-specified subgroup of patients with a high interferon gene signature, investors have remained cautious, given that the trial still failed in the population it was designed to test. That skepticism has continued to filter through into the share price in subsequent sessions, including today's decline.
Analyst Downgrades and Target Cuts Add Pressure
The failed trial triggered a broad reassessment across Wall Street. Guggenheim downgraded ALMS from Buy to Neutral, while Morgan Stanley and Wells Fargo both lowered their price targets, with Wells Fargo cutting its objective from $51 to $25. H.C. Wainwright moved its rating to Buy but reduced its target to $15, reflecting a more tempered view of the lupus program's probability of success. Collectively, these revisions signal a reduced willingness to assign premium value to the company's pipeline, and that sentiment has translated into continued selling pressure on the stock.
Insider Buying Provides Only Temporary Support
Amid the selloff, director Srinivas Akkaraju disclosed a series of substantial open-market purchases totaling more than $10 million, executed through affiliated investment funds. The insider buying briefly fueled a gap-up in the shares, as investors interpreted the transactions as a vote of confidence from a board member. However, the support proved short-lived. The broader overhang from the clinical setback and the revised analyst expectations ultimately outweighed the positive insider signal, and the stock has since resumed its downward trajectory.
Market Context and Trading Activity
Trading in ALMS has been characterized by sharply elevated volume relative to its pre-trial average, consistent with a period of heavy repositioning by institutional and retail investors alike. The stock remains well below its 50-day and 200-day moving averages, which had been anchored at levels above $24 before the collapse, underscoring the technical damage done by the clinical disappointment. The decline has also diverged from broader market activity, reflecting company-specific fundamentals rather than sector-wide or macroeconomic forces, as investors grapple with the reduced visibility on the company's lead asset.
What Comes Next for ALMS
Looking ahead, attention will turn to Alumis's planned end-of-Phase 2 meetings with the U.S. Food and Drug Administration and the European Medicines Agency. The company intends to discuss the design, dosing, size, and biomarker-enrollment criteria for a potential Phase 3 program built around the interferon-high subgroup that showed more encouraging responses. Key questions remain about whether regulators will accept a biomarker-enriched enrollment strategy after a failed all-comers trial, and whether the company can secure the capital needed to advance an expensive late-stage program. Investors will also watch upcoming earnings reports and any further analyst commentary as the clinical story evolves.
Trending AI Robots
For traders seeking a more systematic approach to navigating volatile names like ALMS, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade, allowing users to explore automated approaches matched to their own preferences. Explore the Trending AI Robots to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
ALMS's RSI Indicator sits in oversold zone for 22 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for ALMS just turned positive on September 22, 2026. Looking at past instances where ALMS's MACD turned positive, the stock continued to rise in 15 of 18 cases over the following month. The odds of a continued upward trend are 83%.
Following a +3.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMS advanced for three days, in 100 of 129 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ALMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ALMS entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.050) is normal, around the industry mean (26.780). P/E Ratio (0.166) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (123.457) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ALMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement